指南依从性抗生素治疗与镰状细胞病急性胸部综合征患儿再入院率的关联
结果显示73.6%的住院使用了指南推荐的抗生素方案,且指南依从性治疗与较低的30天全因再入院率相关(OR 0.50,95%CI 0.39-0.64)。
要点
- 指南依从性抗生素方案(大环内酯类联合肠外头孢菌素)使用率为73.6%,医院间差异大(24%-90%)。
- 指南依从性治疗与较低的30天全因再入院率相关(OR 0.50,95%CI 0.39-0.64)。
- 5-9岁儿童指南依从性治疗比例最高(79.8%),19-22岁最低(64.1%)。
核心结论
- 在镰状细胞病合并急性胸部综合征的住院患儿中,指南依从性抗生素治疗与非指南依从性治疗相比,与更低的30天全因再入院率相关。
主要发现
- 指南依从性治疗组30天ACS相关再入院OR为0.71(95%CI 0.50-1.00),全因再入院OR为0.50(95%CI 0.39-0.64)。
关键数值与推荐
- 指南依从性方案定义为大环内酯类联合肠外头孢菌素。
- 非指南依从性方案包括头孢菌素联合大环内酯类与两者均未使用等比较。
临床怎么用
- 对于镰状细胞病合并急性胸部综合征住院患儿,可考虑采用指南推荐的大环内酯类联合肠外头孢菌素方案以降低再入院风险。
- 需关注不同年龄和医院间指南依从性差异,促进指南实施。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acute chest syndrome (ACS) is a common, serious complication of sickle cell disease (SCD) and a leading cause of hospitalization and death in both children and adults with SCD. Little is known about the effectiveness of guideline-recommended antibiotic regimens for the care of children hospitalized with ACS. OBJECTIVES: To use a large, national database to describe patterns of antibiotic use for children with SCD hospitalized for ACS and to determine whether receipt of guideline-adherent antibiotics was associated with lower readmission rates. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study including 14 480 hospitalizations in 7178 children (age 0-22 years) with a discharge diagnosis of SCD and either ACS or pneumonia. Information was obtained from 41 children's hospitals submitting data to the Pediatric Health Information System from January 1, 2010, to December 31, 2016. EXPOSURES: National Heart, Lung, and Blood Institute guideline-adherent (macrolide with parenteral cephalosporin) vs non-guideline-adherent antibiotic regimens. MAIN OUTCOMES AND MEASURES: Acute chest syndrome-related and all-cause 7- and 30-day readmissions. RESULTS: Of the 14 480 hospitalizations, 6562 (45.3%) were in girls; median (interquartile range) age was 9 (4-14) years. Guideline-adherent antibiotics were provided in 10 654 of 14 480 hospitalizations for ACS (73.6%). Hospitalizations were most likely to include guideline-adherent antibiotics for children aged 5 to 9 years (3230 of 4047 [79.8%]) and declined to the lowest level for children 19 to 22 years (697 of 1088 [64.1%]). Between-hospital variation in antibiotic regimens was wide, with use of guideline-adherent antibiotics ranging from 24% to 90%. Children treated with guideline-adherent antibiotics had lower 30-day ACS-related (odds ratio [OR], 0.71; 95% CI, 0.50-1.00) and all-cause (OR, 0.50; 95% CI, 0.39-0.64) readmission rates vs children who received other regimens (cephalosporin and macrolide vs neither drug class). CONCLUSIONS AND RELEVANCE: Current approaches to antibiotic treatment in children with ACS vary widely, but guideline-adherent therapy appears to result in fewer readmissions compared with non-guideline-adherent therapy. Efforts to increase the dissemination and implementation of SCD treatment guidelines are warranted as is comparative effectiveness research to strengthen the underlying evidence base.
引用
- Bundy DG, Richardson TE, Hall M, et al. Association of Guideline-Adherent Antibiotic Treatment With Readmission of Children With Sickle Cell Disease Hospitalized With Acute Chest Syndrome. JAMA Pediatr. 2017. PMID: 28892533. doi:10.1001/jamapediatrics.2017.2526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。